21 setembro 2020

Pandemias, vacinas e lucro das empresas


We estimate a model of damage to corporate earnings from COVID-19. An unexpected pandemic lowers current earnings due to costly mitigation and reduces growth rates. Damage depends on the expected arrival of a vaccine that reverts earnings to normal. Using this model, we infer from analysts' earnings forecasts that, as of mid-May 2020, an effective vaccine is expected in 0.96 years (95% bootstrap CI [0.72,1.72]). Growth rates are on average 25% lower in the interim. Levered and face-to-face industries would benefit the most from a vaccine arrival. Analysts' expectations imply that the vaccine expected for the middle of 2021 is a silver bullet for corporate earnings. 

Pandemics, Vaccines and Corporate EarningsHarrison Hong, Jeffrey Kubik, Neng Wang, Xiao Xu, and Jinqiang YangNBER Working Paper No. 27829September 2020 

Nenhum comentário:

Postar um comentário